Fig. 5: Multiplex (CK, CD45, Ki67, DAPI, PDL1, PDL2) immunohistochemistry in baseline and surgery tumor samples from patients (n = 37) included in the NeoRHEA study. | Nature Communications

Fig. 5: Multiplex (CK, CD45, Ki67, DAPI, PDL1, PDL2) immunohistochemistry in baseline and surgery tumor samples from patients (n = 37) included in the NeoRHEA study.

From: Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study

Fig. 5

a Immune (CK-/CD45 + ), stroma (CK-/CD45-/Ki67-) and tumor (CK + /CD45-) were defined. The percentage of the respective cells expressing Ki67, PDL1 and PDL2, respectively, is shown on the Y-axis. Each sample is represented by one point; patients with samples in both time points are connected via a line. CK: cytokeratin, DAPI: 4’,6-diamidino-2-phenylindole, PD-L1: Programmed death-ligand 1, PD-L2: Programmed death-ligand 2. Box plots show the median (horizontal line), interquartile range (box = 25th to 75th percentile), and whiskers extending to the smallest and largest values within 1.5 × IQR from the lower and upper quartiles, respectively; points beyond the whiskers represent outliers. Two-sided unpaired Wilcoxon was used, no adjustments were made for multiple comparisons. b Visual representation of stroma/tumor segmentation masks, classifications and cell-level segmentation for mIHC analysis.

Back to article page